Arvinas Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Randy Teel

Algemeen directeur

US$3.8m

Totale compensatie

Percentage CEO-salaris	12.58%
Dienstverband CEO	no data
Eigendom CEO	0.06%
Management gemiddelde ambtstermijn	2.1yrs
Gemiddelde ambtstermijn bestuur	6.3yrs

Recente managementupdates

Recent updates

Companies Like Arvinas (NASDAQ:ARVN) Are In A Position To Invest In Growth

Jan 27

Arvinas: Approvable, But Asset Looks Mediocre, Initiating With A Hold Rating

Nov 24

Improved Revenues Required Before Arvinas, Inc. (NASDAQ:ARVN) Stock's 26% Jump Looks Justified

Sep 09

We're Not Very Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Rate

Jun 01

Arvinas, Inc.'s (NASDAQ:ARVN) Shares Bounce 37% But Its Business Still Trails The Industry

May 01

Phase III And PROTAC Data Will Advance Pipeline Despite Hurdles

Mar 24 Successful trials and partnerships in oncology could support Arvinas' transition to commercial operations, driving growth and revenue potential.

Arvinas: Veritac-2 ITT Failure Confirms Limited Prospects

Mar 14

Arvinas, Inc. (NASDAQ:ARVN) Not Doing Enough For Some Investors As Its Shares Slump 56%

Mar 12

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aug 02

Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive

Jul 12

Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Jun 27

Arvinas: Behind The Huge Rally

Mar 03

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Feb 25

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

Aug 13

Analyse CEO-vergoeding

Hoe is Randy Teel's beloning veranderd ten opzichte van Arvinas's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2025	n/a	n/a	-US$58m
Jun 30 2025	n/a	n/a	-US$73m
Mar 31 2025	n/a	n/a	-US$47m
Dec 31 2024	US$4m	US$475k	-US$199m

Compensatie versus markt: De totale vergoeding ($USD 3.78M ) Randy } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.30M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Randy te vergelijken met de prestaties van het bedrijf.

CEO

Randy Teel (45 yo)

no data

Tenure

US$3,776,333

Compensatie

Dr. Randy Teel, Ph.D. served as Interim Chief Financial Officer and Treasurer at Arvinas, Inc. since February 29, 2024 until April 2024 and served as its Chief Business Officer since April 2024 until Febru...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Randy Teel	CEO, President & Director	no data	US$3.78m	0.062% $ 477.0k
Andrew Saik	CFO & Treasurer	1.7yrs	US$3.72m	0.026% $ 201.3k
Angela Cacace	Chief Scientific Officer	1.7yrs	US$2.97m	0.052% $ 397.0k
Noah Berkowitz	Chief Medical Officer	1.9yrs	US$6.10m	0.024% $ 183.7k
David Loomis	VP & Chief Accounting Officer	no data	geen gegevens	0.012% $ 89.6k
Jeff Boyle	Vice President of Investor Relations	5.1yrs	geen gegevens	geen gegevens
Jared Freedberg	General Counsel & Corporate Secretary	2.1yrs	geen gegevens	geen gegevens
Steve Weiss	Senior VP & Chief Human Resources Officer	no data	geen gegevens	geen gegevens
Lisa Sinclair	Senior Vice President of Corporate Operations	3.5yrs	geen gegevens	geen gegevens
Paul McInulty	Senior Vice President of Regulatory Affairs	3.3yrs	geen gegevens	geen gegevens
Alexander Santini	Interim Chief Commercial Officer & Senior VP of Global and U.S. Market Access	no data	geen gegevens	geen gegevens
Kelly Page	Senior VP & Global Head of Oncology Strategy and Program Leadership	2.9yrs	geen gegevens	geen gegevens

2.1yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ARVN wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Randy Teel	CEO, President & Director	no data	US$3.78m	0.062% $ 477.0k
Edward Kennedy	Independent Director	7.6yrs	US$451.53k	0.082% $ 632.4k
Lillian Siu	Member of Scientific Advisory Board	6.3yrs	geen gegevens	geen gegevens
Leslie Norwalk	Independent Director	6.6yrs	US$451.53k	0.016% $ 120.1k
Briggs Duncan W. Morrison	Chairman & Lead Director	7.7yrs	US$480.39k	0.093% $ 719.4k
Laurie Smaldone Alsup	Independent Director	6.3yrs	US$456.53k	0.016% $ 120.1k
Adam Boxer	Member of Scientific Advisory Board	6.3yrs	geen gegevens	geen gegevens
Lennart Mucke	Member of Scientific Advisory Board	6.3yrs	geen gegevens	geen gegevens
Benjamin Neel	Member of Scientific Advisory Board	6.3yrs	geen gegevens	geen gegevens
Linda Bain	Independent Director	5.7yrs	US$461.53k	0.016% $ 120.1k
John Houston	Director	8.4yrs	US$12.75m	1.42% $ 10.9m
Ian Taylor	Chairman of Scientific Advisory Board	1.1yrs	US$4.22m	0.18% $ 1.4m

6.3yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ARVN wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.3 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/02/23 07:35
Aandelenkoers aan het einde van de dag	2026/02/23 00:00
Inkomsten	2025/09/30
Jaarlijkse inkomsten	2024/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details over het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina; we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

"}]}

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Arvinas, Inc. wordt gevolgd door 28 analisten. 16 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Peter Lawson	Barclays
Etzer Darout	Barclays
Tazeen Ahmad	BofA Global Research

Arvinas Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Arvinas, Inc. Announces Management Changes

Arvinas Announces Retirement of John Houston, Ph.D., Chairperson as President

Insufficient new directors

Arvinas, Inc. Announces John Young Decides to Resign from its Board of Directors and Compensation Committee, Effective June 30, 2025

Arvinas, Inc., Annual General Meeting, Jun 25, 2025

Insider recently sold US$74k worth of stock

Recent updates

Arvinas, Inc. to Report Q4, 2025 Results on Feb 24, 2026

Arvinas, Inc. Announces Management Changes

Companies Like Arvinas (NASDAQ:ARVN) Are In A Position To Invest In Growth

Price target decreased by 32% to US$12.44

Arvinas, Inc. Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab At the 2025 American Society of Hematology Annual Meeting and Exposition

Arvinas: Approvable, But Asset Looks Mediocre, Initiating With A Hold Rating

Arvinas, Inc. to Report Q3, 2025 Results on Nov 05, 2025

Arvinas, Inc. Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-Mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer

Arvinas, Inc. Announces New Patient-Reported Outcomes (PRO) Data from the Phase 3 Veritac-2 Clinical Trial Evaluating Vepdegestrant

Arvinas, Inc. Presents Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Arvinas, Inc. Approves Reduction in Workforce of Approximately 15% Across Roles in Functional Areas of the Company Primarily Related to Vepdegestrant Commercialization

Improved Revenues Required Before Arvinas, Inc. (NASDAQ:ARVN) Stock's 26% Jump Looks Justified

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Arvinas, Inc. to Report Q2, 2025 Results on Aug 06, 2025

Arvinas Announces Retirement of John Houston, Ph.D., Chairperson as President

Insufficient new directors

Arvinas, Inc. Announces John Young Decides to Resign from its Board of Directors and Compensation Committee, Effective June 30, 2025

Logos Global Management LP Issues a Letter to the Board of Arvinas, Inc.

Arvinas, Inc. Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

Arvinas and Pfizer Announce Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

We're Not Very Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Rate

Price target decreased by 7.9% to US$34.24

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Arvinas, Inc.'s (NASDAQ:ARVN) Shares Bounce 37% But Its Business Still Trails The Industry

Arvinas, Inc., Annual General Meeting, Jun 25, 2025

Arvinas, Inc. to Report Q1, 2025 Results on May 01, 2025

Arvinas Announces Results from the Veritac-2 Trial Selected as Late-Breaking Oral Presentation At the 2025 American Society of Clinical Oncology Annual Meeting

Price target decreased by 8.9% to US$39.47

Arvinas, Inc. Presents First-In-Human Data for Investigational Oral Protac ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

Insider recently sold US$74k worth of stock

Phase III And PROTAC Data Will Advance Pipeline Despite Hurdles

Arvinas: Veritac-2 ITT Failure Confirms Limited Prospects

Price target decreased by 18% to US$50.05

Arvinas, Inc. (NASDAQ:ARVN) Not Doing Enough For Some Investors As Its Shares Slump 56%

New major risk - Share price stability

Arvinas, Inc. and Pfizer Inc. Announce Positive Topline Results from Phase 3 Veritac-2 Clinical Trial

Chairperson recently sold US$524k worth of stock

Consensus EPS estimates upgraded to US$3.69 loss

Full year 2024 earnings: EPS exceeds analyst expectations

Arvinas, Inc. to Report Q4, 2024 Results on Feb 11, 2025

Arvinas, Inc. Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant

Arvinas' Vepdegestrant: Why The Data May Not Hold Up

Arvinas (NASDAQ:ARVN) Is In A Good Position To Deliver On Growth Plans

Arvinas and Pfizer Announces Initial Phase 1B Data from the Tactive-U Sub-Study of Vepdegestrant in Combination with Abemaciclib At 2024 San Antonio Breast Cancer Symposium

Investors Still Waiting For A Pull Back In Arvinas, Inc. (NASDAQ:ARVN)

Consensus revenue estimates increase by 20%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause

Consensus revenue estimates increase by 23%

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive

Arvinas, Inc.(NasdaqGS:ARVN) dropped from Russell Small Cap Comp Value Index

Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Arvinas, Inc. Appoints Andrew Saik as Treasurer

Arvinas, Inc. Announces Presentations for Two of Its PROTAC Investigational Programs Targeting BCL6 and LRRK2

Arvinas Announces Promotions of Ian Taylor to President of Research and Development and Angela Cacace to Chief Scientific Officer

Arvinas, Inc. Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE)

Consensus revenue estimates increase by 17%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Arvinas, Inc. Appoints Randy Teel as Chief Business Officer

Arvinas, Inc., Annual General Meeting, May 29, 2024

Consensus EPS estimates upgraded to US$5.13 loss

Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee

Arvinas: Behind The Huge Rally

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$5.76 loss

Arvinas, Inc. announced that it has received $349.999871 million in funding from a group of investors